Key Takeaways
- Codexis (CDXS) delivered Q4 earnings per share of $0.11, surpassing analyst expectations by $0.10
- Fourth-quarter revenue reached $38.9 million, representing an 81% year-over-year increase and exceeding projections of $35.83 million
- The revenue boost was primarily driven by a $37.8 million Technology Transfer Agreement completed with Merck
- The company’s annual net loss for 2025 improved to $44.0 million compared to $65.3 million in 2024
- Management projects 2026 revenues between $72 million and $76 million, with sufficient cash to operate through 2027
On March 11, 2026, Codexis unveiled its fourth-quarter and full-year 2025 financial performance, exceeding analyst projections on both the top and bottom lines. Shares responded positively, gaining 2.4% to reach $1.27.
The biotechnology company posted earnings per share of $0.11 for Q4, handily beating the analyst consensus of $0.01 by a dime. Quarterly revenues totaled $38.9 million, surpassing the Street’s $35.83 million forecast and marking an impressive 81% climb from the $21.5 million recorded in the year-ago period.
The substantial revenue increase was largely attributable to a $37.8 million Technology Transfer Agreement finalized with Merck during the quarter, which significantly impacted the quarterly performance.
Looking at the full-year picture, Codexis generated total revenue of $70.4 million for 2025, representing a 19% increase from the $59.3 million achieved in 2024. The company’s product gross margin showed meaningful improvement, expanding to 64% from the previous year’s 56%.
The annual net loss contracted to $44.0 million, or $0.50 per share, representing a notable improvement from the $65.3 million loss, or $0.89 per share, recorded in 2024. Notably, Q4 marked a profitable quarter with net income of $9.6 million, a sharp turnaround from the $10.4 million loss posted in the comparable quarter last year.
Operating expenses showed mixed results. Selling, general and administrative expenses declined to $47.1 million for the year from $55.1 million in 2024, benefiting from reduced stock-based compensation and legal costs. Conversely, research and development investments increased to $52.3 million from $46.3 million.
The company also incurred $3.4 million in non-recurring restructuring expenses related to a workforce reduction implemented in November 2025.
Financial Position and Forward Outlook
Codexis closed 2025 with $78.2 million in cash, cash equivalents and short-term investments. Management believes this liquidity provides adequate financial runway to operate through year-end 2027.
For the current year, the company is projecting total revenues in the range of $72 million to $76 million.
From a business development perspective, Codexis is actively engaged with more than 40 corporate partners across 55 distinct opportunities. CEO Alison Moore highlighted that customer discussions have progressed beyond initial feasibility assessments toward more substantive contract negotiations.
The company has secured a lease for a Good Manufacturing Practice (GMP) facility with kilogram-scale production capacity. Retrofit construction work is scheduled to commence in the latter half of 2026, with the facility expected to reach full operational capability by the end of 2027.
Codexis has also established a partnership agreement with Axolabs, marking its third contract development and manufacturing organization (CDMO) collaboration, to assess its ECO Synthesis platform at Axolabs’ production facilities.
Market Sentiment and Ownership Trends
Despite the positive earnings surprise, Wall Street analysts maintain a cautious stance. Weiss Ratings confirmed a “Sell” rating on January 21, and the MarketBeat consensus rating remains at “Sell.”
The stock currently trades nearer its 52-week low of $0.96 than its 52-week high of $3.87, with a market capitalization of $114.7 million. Technical indicators show the 50-day moving average at $1.39 and the 200-day moving average at $1.90.
Institutional ownership has been trending upward. Millennium Management dramatically increased its holdings by 3,376.5% during Q3. Renaissance Technologies expanded its position by 137.5% in Q4. Institutional investors collectively control 78.54% of outstanding shares.
Looking ahead, the company aims to secure a licensing agreement with a major pharmaceutical partner in the second half of 2026 and plans to showcase stereoisomer control research findings at the 2026 TIDES USA annual conference.
